Helicos' Q2 Grant Revenue Rises; Reagent Issues Affect Orders | GenomeWeb
This article has been updated to include comments from a conference call and an updated stock quote.
 
NEW YORK (GenomeWeb News) – Helicos BioSciences this morning reported that its grant revenues rose 75 percent for the three-month period ended June 30, while its net loss increased by 47 percent.
 
The Cambridge, Mass.-based firm brought in grant revenue of $251,000 compared to $143,000 in the second quarter of 2007. Helicos claimed no revenues from product sales during the quarter.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.